Please note that the final Program might differ in some details.
This new type of session will include the presentation of particularly interesting clinical cases. Each of the four sessions (Aggressive NHL, Indolent NHL and CLL, Hodgkin Lymphoma, Difficult Pathological Cases) will involve world-renowned specialists in the discussion who will bring their knowledge and expertise to the benefit of our participants.
Thanks to the virtual format it will be possible to hold the two Educational symposia on two different days, allowing the participants to attend both of them.
Each symposium will extensively address a specific topic, explained in 3 lectures by experts who will explore and scrutinize different aspects of the chosen topics.
High-risk follicular lymphoma
Upfront identification of high risk follicular lymphoma - Carla Casulo, Rochester, NY (USA)
Vulnerabilities in the tumor and microenvironment in follicular lymphoma - Elias Campo, Barcelona (Spain)
High risk follicular lymphoma: treatment options - Brad Kahl, Saint Louis, MO (USA)
Immunotherapy
Optimizing CAR T-cell therapy in lymphoma - Gilles Salles, New York, NY (USA)
Allogeneic stem cell transplant in non-Hodgkin lymphomas: still an indication? - Peter Dreger, Heidelberg (Germany)
Bi-specific antibodies for the treatment of lymphoma: promises and challenges - Stephen Schuster, Philadelphia, PA (USA)
As usual, also this time the themes of the general sessions is defined on the basis of the abstracts received and accepted for oral presentations.
Each abstract was evaluated by at least 8 experts from all over the world. To them goes the Organizing Committee's gratitude and appreciation for the friendly cooperation and professional expertise.
The subjects identified and set are as follows:
- NEW THERAPEUTICS
- LYMPHOMA IMAGING
- AGGRESSIVE LYMPHOMAS
- CHRONIC LYMPHOCYTIC LEUKEMIA
- PEDIATRIC LYMPHOMAS
- LYMPHOMA BIOLOGY
- AGGRESSIVE EXTRANODAL ENTITIES
- PERIPHERAL T/NK-CELL LYMPHOMAS
- MANTLE CELL LYMPHOMA
- HODGKIN LYMPHOMA
- INDOLENT LYMPHOMAS
- CAR-T CELL THERAPY
The Keynote lectures are among the most significant moments of the Congress and are dedicated to three prominent individuals engaged in the study of lymphomas, in the development of therapeutic strategies targeting lymphomas and in particular, those recognised for their important contributions throughout the history of the ICML. These lectures are assigned to distinguished scientists and researchers by the Organizing Committee, with the help of the Advisory Board, on the basis of various criteria.
HENRY KAPLAN MEMORIAL LECTURE
Towards control of chronic lymphocytic leukemia with targeted agents - Michael Hallek, Cologne (Germany)
This lecture will summarize the incredible development of CLL, in which astonishing progresses have recently been achieved both in the biological understanding as well as in the clinical outcome. Future avenues for further improving the therapeutic results will also be outlined.
GIANNI BONADONNA MEMORIAL LECTURE
The architecture of liquid biopsy research for lymphoma monitoring - Ash A. Alizadeh, Stanford, CA (USA)
Quantification and qualification of circulating tumor material is an emerging biomarker of lymphoma that may be used for tumor load estimation, clonal evolution monitoring, treatment response assessment and early identification of clinically occult relapse. The topic will also be discussed in many proffered papers at this ICML.
JOHN ULTMANN MEMORIAL LECTURE
Immune Suppression and Dysfunction in the Tumor Microenvironment in Lymphoma - Stephen M. Ansell, Rochester, MN (USA)
The tumor microenvironment in lymphoma typically contains substantial numbers of intratumoral T-cells and identification of activated rather than exhausted T-cells may be an effective way of predicting responses to immunotherapy.
“Meet the Professor” sessions are 45-minute lessons (30 minutes frontal lecture and 15 minutes live Q&A) that allow participants to meet internationally recognized experts and gain a deeper insight into topics of particular interest.
- What's new in peripheral T-cell lymphomas
Stefano Luminari, Reggio Emilia (Italy) - Molecular classification of aggressive lymphomas - past, present, future
Bjoern Chapuy, Göttingen (Germany) - Personalized medicine for Hodgkin lymphoma: mitigating toxicity while preserving cure
Peter W.M. Johnson, Southampton (UK) - Recognizing but not harming. Borderline B-cell lymphoid proliferations
Letitia Quintanilla-Martinez de Fend, Tübingen (Germany) - Sequencing of myeloma therapy: finding the right path among many standards
S.Vincent Rajkumar, Rochester, MN (USA) - Molecular diagnostics and reporting in lymphoid malignancies: current status and beyond
Richard Rosenquist Brandell, Stockholm (Sweden) - Cutaneous T-cell lymphoma – an update 2021
Werner Kempf, Zürich (CH) - Langerhans Cell Histiocytosis: Version 2021
Carl E. Allen, Houston, TX (USA) - New drugs and pharmacological interactions in real life
Anastasios Stathis, Bellinzona (CH) - Use of available prognostic scores in treatment decision: beyond standard prognostic scores to include molecular/genetics/imaging
John F. Seymour, Melbourne (Australia) - Mantle cell lymphoma - advances in molecular biology, prognostication and treatment approaches
Martin Dreyling, Munich (Germany)
The collection of articles written by speakers of the Educational symposia and Meet the Professor sessions represents the content of the Educational Book, published by John Wiley and Sons, Ltd.
ICML Big Debates are traditionally devoted to a pivotal question.
This year world renowned experts will discuss "DLBCL: one disease, one treatment?".
Click here for more details
AACR-ICML joint session: Artificial intelligence in lymphoma diagnosis and treatment
Artificial intelligence and medicine: past and future - Luca Gambardella, Bellinzona (Switzerland)
Artificial intelligence and pathology - Pierre Brousset, Toulouse (France)
Use of deep learning to analyse and exploit molecular data - Dan A. Landau, New York, NY (USA)
Industry vision of Machine Learning to enhance clinical development - Paul Trichelair, Paris (France)
UCLI-ICML joint session: New data on T-cell and other lymphomas
T-cell lymphoma biopathology: what is new? - Laurence de Leval, Lausanne (Switzerland)
The epidemiology of malignant lymphoid diseases in China - Yu-qin Song, Beijing (China)
Recent advances in Extranodal Natural Killer/T-Cell Lymphoma: experiences from the SYSUCC
- Qing-qing Cai, Guangzhou (China)
New treatment options in T-cell lymphoma - Stefano Luminari, Reggio Emilia (Italy)
The changing faces of EBV+ T/NK-cell lymphomas: diagnostic challenges and advances
- Xiao-qiu Li, Shanghai (China)
IBSA Foundation Special Forum
Vaccines and monoclonals to regain our freedom - Rino Rappuoli, Siena (Italy)
16-ICML Pediatric session
Current status and challenges in the diagnosis of childhood NHL - Wolfram Klapper, Kiel (Germany)
16-ICML Special session
Lymphoma treatment in developing countries - Andrea Biondi, Monza (Italy)
Workshops organised by the International Lymphoma Radiation Oncology Group (ILROG)
Organised in collaboration with the International Lymphoma Radiation Oncology Group (ILROG), the workshops represent an opportunity for continuous learning not only for radiation oncologists, but also for medical oncologists and haematologists.
Sunday, June 20
Innovation in radiotherapy – new dose/fractionation schedules
Chair: Lena Specht, Copenhagen (Denmark)
Radiation doses in the treatment of lymphomas – what is the evidence?
Peter Hoskin, Manchester (UK)
Low-dose regimens – new fractionation schemes for indolent lymphomas
Joachim Yahalom, New York, NY (USA)
Fewer but larger fractions in lymphoma radiotherapy – experience from the COVID emergency fractionation
Lena Specht, Copenhagen (Denmark)
Monday, June 21
The evolving role of Radiotherapy in the salvage treatment for lymphoma in the era of CAR-T therapy
Chair: Bouthaina S. Dabaja, Houston, TX (USA)
Radiation Prior to Immune-Cellular Therapy: The Science Behind Sublethal Immunogenic Cell Death
Bouthaina S. Dabaja, Houston, TX (USA)
Optimal integration of RT in salvage therapy for relapsed / refractory lymphoma (including CAR-T)
Richard Tsang, Toronto, ON (Canada)
Clinical trials combining RT and CAR-T
George Mikhaeel, London (UK)
This is a lecture held at the closure of the Scientific Program that summarizes and highlights the themes addressed during the congress.
The participants will receive a series of hints and considerations that will facilitate the identification and understanding of the new knowledge presented and discussed during the Conference.
Take Home Messages - James O. Armitage, Omaha, NE (USA)
The 16-ICML Industry Program is intended only for healthcare professionals involved in the study and treatment of lymphoid neoplasms.